Vyleesi (Bremelanotide) Guide for HSDD 2026
Complete Guide & Evidence (2026)
The complete guide to Vyleesi (Bremelanotide), the FDA-approved peptide for Hypoactive Sexual Desire Disorder in women.
What Is Vyleesi (Bremelanotide) Guide?
Vyleesi (generic name Bremelanotide, originally PT-141) is an FDA-approved injectable peptide designed to treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
Unlike PDE5 inhibitors (Viagra) which alter blood flow, Vyleesi works centrally in the brain by binding to melanocortin receptors, lighting up neural pathways associated with sexual arousal and desire.
Key Biohacking Mechanics
Dosing Protocol
SubQ injection into abdomen or thigh.
At least 45 minutes before anticipated activity.
No more than ONE dose per 24 hours, max 8 per month.
Note: Severe nausea occurs in ~40% of patients. Antiemetic medication or slow titration is often required. Do NOT exceed dose limits — it severely spikes blood pressure.
Side Effects & Safety
Vital Protocol FAQs
Guide FAQs
The complete guide to Vyleesi (Bremelanotide), the FDA-approved peptide for Hypoactive Sexual Desire Disorder in women.
Yes. Shotlee supports tracking Vyleesi doses, side effects, and health metrics. It is free to use.
Track Your Vyleesi Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.